Bausch Health Companies Inc. (TSX:BHC)
Market Cap | 2.41B |
Revenue (ttm) | 13.99B |
Net Income (ttm) | -57.49M |
Shares Out | n/a |
EPS (ttm) | -0.16 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 393,612 |
Average Volume | 511,711 |
Open | 6.79 |
Previous Close | 6.82 |
Day's Range | 6.47 - 6.95 |
52-Week Range | 5.45 - 13.74 |
Beta | 0.43 |
RSI | 36.11 |
Earnings Date | Apr 30, 2025 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]
Financial Performance
In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.
Financial numbers in USD Financial StatementsNews

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:B...
Bausch health outlines 2025 guidance with 4-5% revenue and EBITDA growth amid strategic refinancing
Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC) Q1 2025 Earnings Conference Call April 30, 2025 5:00 PM ETCompany ParticipantsGaren Sarafian - IRThomas Appio -...
Bausch Health Companies Inc. 2025 Q1 - Results - Earnings Call Presentation
The following slide deck was published by Bausch Health Companies Inc.

Bausch Health Announces First Quarter 2025 Results
First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies...
Bausch Health Companies Q1 2025 Earnings Preview

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System
A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)...
Notable healthcare headlines for the week: Merck, Roche and Bausch Health in focus
Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4

Bausch Health Learns Icahn Has 34% Economic Interest in Shares
Activist investor Carl Icahn has tightened his hold on pharmaceutical company Bausch Health.
Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Bausch Health says Carl Icahn has exposure to about 34% of company's shares
Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday.
Bausch Health jumps after Carl Icahn’s 34% stake

Bausch Health Announces Filing of Supplement to Proxy Statement
Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 ...

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ...

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today...
Bausch Health Companies Inc (BHC) Adopts Shareholder Rights Plan | BHC stock news
Bausch Health Companies Inc (BHC) Adopts Shareholder Rights Plan | BHC stock news

Bausch Health Announces Adoption of Shareholder Rights Plan
LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") announces today that its board of directors (the "Board") has approve...
Bausch Health Companies Inc (BHC) Launches 2025 ASPIRE HIGHER Scholarship Program | BHC stock news
Bausch Health Companies Inc (BHC) Launches 2025 ASPIRE HIGHER Scholarship Program | BHC stock news

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausc...

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that it has signed a letter of intent with the pan-Ca...
Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagno...
Bausch Health Companies Inc (BHC) to Announce First Quarter Results on April 30, 2025
Bausch Health Companies Inc (BHC) to Announce First Quarter Results on April 30, 2025

Bausch + Lomb recalls some of its implantable eye lenses
Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.

Bausch + Lomb Recalls EnVista Intraocular Lenses
The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular lenses on its enVista platform.